With several long-acting HIV treatments in the works, the newest drugs emphasize convenience
As people live for decades with HIV, drugmakers respond with drugs that can be taken every few weeks
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2025 American Chemical Society
May 13, 2019 Cover
Volume 97, Issue 19
As people live for decades with HIV, drugmakers respond with drugs that can be taken every few weeks
Cover image:A pair of hands holding pills and a syringe.
Credit: Will Ludwig/C&EN/Shutterstock
Volume 97 |
Issue 19
Drug Development
The struggle to keep women in academia
Incremental gains in the number of women in chemistry faculty can’t outpace the growing number who choose other careers
Vladimir Ipatieff is the catalysis superhero you’ve never heard of
Russian-born scientist revolutionized chemistry by helping launch heterogeneous catalysis more than a century ago. Today, hardly anyone knows his name
-
How to combat impostor syndrome
Jen Heemstra on how to turn our negative thoughts into positive actions
-
Foghorn Therapeutics takes aim at chromatin hijackers to stop cancer
The start-up, cofounded by Cigall Kadoch, is drugging a molecular machine called BAF, part of the chromatin regulatory system
-
A-STAR’s Jackie Ying wants academics to think more like entrepreneurs
Head of NanoBio Lab aims to move inexpensive medical diagnostics from the lab bench to the market
ADVERTISEMENT
Science Concentrates
Governments endorse global PFOA ban, with some exemptions
Restrictions placed on firefighting foam with PFOA, PFOS, or both
